CL2020002342A1 - Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada - Google Patents

Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada

Info

Publication number
CL2020002342A1
CL2020002342A1 CL2020002342A CL2020002342A CL2020002342A1 CL 2020002342 A1 CL2020002342 A1 CL 2020002342A1 CL 2020002342 A CL2020002342 A CL 2020002342A CL 2020002342 A CL2020002342 A CL 2020002342A CL 2020002342 A1 CL2020002342 A1 CL 2020002342A1
Authority
CL
Chile
Prior art keywords
treatment
antibodies
pustular psoriasis
generalized pustular
generalized
Prior art date
Application number
CL2020002342A
Other languages
English (en)
Inventor
Janine Lamar
Steven John Padula
Christian Thoma
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020002342A1 publication Critical patent/CL2020002342A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al tratamiento de o el alivio de los signos y síntomas de un brote en fase aguda de la psoriasis pustulosa generalizada (GPP) con anticuerpos anti-IL36R.
CL2020002342A 2018-03-14 2020-09-10 Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada CL2020002342A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US201862683720P 2018-06-12 2018-06-12
US201862699274P 2018-07-17 2018-07-17
US201862729518P 2018-09-11 2018-09-11

Publications (1)

Publication Number Publication Date
CL2020002342A1 true CL2020002342A1 (es) 2020-12-18

Family

ID=65904556

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002342A CL2020002342A1 (es) 2018-03-14 2020-09-10 Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada

Country Status (13)

Country Link
US (2) US20190284285A1 (es)
EP (1) EP3765513A1 (es)
JP (2) JP7404256B2 (es)
KR (1) KR102768040B1 (es)
CN (1) CN112272674A (es)
AU (1) AU2019236105B2 (es)
BR (1) BR112020016738A2 (es)
CA (1) CA3093692A1 (es)
CL (1) CL2020002342A1 (es)
IL (1) IL277215B2 (es)
MX (1) MX2020009544A (es)
PH (1) PH12020551444A1 (es)
WO (1) WO2019177888A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745898C2 (ru) 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
IL280013B2 (en) 2018-07-16 2026-05-01 Regeneron Pharmaceuticals Inc Anti-IL36R antibodies
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
EA202192405A1 (ru) * 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
WO2022026829A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
CN112180007B (zh) * 2020-09-16 2023-08-18 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
KR20230079268A (ko) * 2020-09-30 2023-06-05 베링거 인겔하임 인터내셔날 게엠베하 만성 염증성 통증의 치료를 위한 항-il-36r 항체
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
MX2023010289A (es) * 2021-03-04 2023-09-11 Boehringer Ingelheim Int Uso de anticuerpos anti-il-36r en el tratamiento de la psoriasis pustulosa generalizada.
EP4305207A2 (en) * 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
AU2022274319A1 (en) * 2021-05-12 2024-01-04 Anaptysbio, Inc. Antibody composition
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
CN115327130A (zh) * 2022-07-25 2022-11-11 深圳市妇幼保健院 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
DE19733389C2 (de) 1997-08-01 1999-08-19 Deutsches Krebsforsch Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
CA2499891A1 (en) 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090270480A1 (en) 2005-12-28 2009-10-29 Bernard Amegadzie Markers and Methods for Assessing and Treating Psoriasis and Related Disorders
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
WO2008133857A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
BRPI0813966A8 (pt) 2007-06-29 2016-02-10 Schering Corp Usos de mdl-1
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
AU2008308442B2 (en) 2007-10-06 2015-01-22 Arbitron, Inc. Gathering research data
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
CA2801917C (en) 2010-06-03 2017-04-25 Abbvie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
RS67639B1 (sr) * 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
JP6796773B2 (ja) 2014-07-30 2020-12-09 ツムトー バイオロジクス、インコーポレイテッド 非フコシル化タンパク質および方法
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
RU2745898C2 (ru) 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
DK3285831T3 (da) 2015-04-24 2024-05-27 Shl Medical Ag Underenhed af en medikamenttilførselsanordning og en medikamenttilførselsanordning
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
EP3397287B8 (en) 2015-12-30 2025-07-23 F. Hoffmann-La Roche AG Formulations with reduced degradation of polysorbate
US20180273627A1 (en) * 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
CN107362351B (zh) 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL280013B2 (en) 2018-07-16 2026-05-01 Regeneron Pharmaceuticals Inc Anti-IL36R antibodies
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
EA202192405A1 (ru) 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
KR102708558B1 (ko) 2019-06-20 2024-09-24 삼성전자주식회사 수직형 메모리 장치
WO2021087245A1 (en) 2019-10-30 2021-05-06 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
KR20230079268A (ko) 2020-09-30 2023-06-05 베링거 인겔하임 인터내셔날 게엠베하 만성 염증성 통증의 치료를 위한 항-il-36r 항체

Also Published As

Publication number Publication date
IL277215B2 (en) 2025-10-01
WO2019177888A1 (en) 2019-09-19
KR102768040B1 (ko) 2025-02-17
US20190284285A1 (en) 2019-09-19
IL277215B1 (en) 2025-06-01
MX2020009544A (es) 2020-10-05
US20210087285A1 (en) 2021-03-25
US12503512B2 (en) 2025-12-23
CA3093692A1 (en) 2019-09-19
AU2019236105A1 (en) 2020-08-27
BR112020016738A2 (pt) 2020-12-15
CN112272674A (zh) 2021-01-26
JP2024028951A (ja) 2024-03-05
AU2019236105B2 (en) 2025-07-31
JP7404256B2 (ja) 2023-12-25
JP2021517566A (ja) 2021-07-26
JP7673168B2 (ja) 2025-05-08
IL277215A (en) 2020-10-29
KR20200131871A (ko) 2020-11-24
EP3765513A1 (en) 2021-01-20
PH12020551444A1 (en) 2021-08-23

Similar Documents

Publication Publication Date Title
PH12020551444A1 (en) Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
CL2021001685A1 (es) Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CL2021003373A1 (es) Nuevos inhibidores de egfr
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CL2021003353A1 (es) Tratamiento conjunto antineoplásico.
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
CR20160199A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2021003422A1 (es) Anticuerpos anti il-13ra2 y usos de los mismos (divisional 201902323).
CO2021000092A2 (es) Anticuerpos que comprenden un polipéptido insertado en la región 3 del marco
MX392703B (es) Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.
BR112017022281A2 (pt) métodos para tratar câncer